Karyopharm TherapeuticsKPTI
About: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Employees: 279
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,110% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $127K
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
39% more capital invested
Capital invested by funds: $13.7M [Q1] → $19M (+$5.32M) [Q2]
8.2% more ownership
Funds ownership: 42.92% [Q1] → 51.13% (+8.2%) [Q2]
4% more funds holding
Funds holding: 47 [Q1] → 49 (+2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Baird Michael Ulz | 296%upside $25 | Outperform Maintained | 12 Aug 2025 |
Financial journalist opinion
Based on 6 articles about KPTI published over the past 30 days
